TECH logo

Bio-Techne

TECH · What the business does, what can go wrong, and how options sellers approach it

What it does

Bio-Techne is a life sciences company based in Minnesota. It makes the tools and materials that scientists use to study proteins, cells and genes, and it supplies tests used in diagnostics.

Its customers include pharmaceutical and biotech companies, universities and research institutes, and diagnostic labs.

How it makes money

Most revenue comes from selling consumables: products that researchers use up and reorder, such as reagents, antibodies and assay kits. It also sells instruments, which tend to be bought less often but can pull in follow-on consumable purchases.

The diagnostics side earns money from selling testing components and molecular tests to labs and clinical customers. Sales are spread across the United States, Europe and Asia-Pacific.

Why investors own it

  • Recurring demand: Research labs reorder consumables regularly, which can make revenue more stable than pure equipment sales.
  • Specialized products: Many of its reagents are well known and trusted in research, and scientists can be reluctant to switch once a method is validated.
  • Exposure to long-term themes: Drug discovery, cell and gene therapy and precision medicine all rely on the kinds of tools it sells.

What can go wrong

  • Funding cycles: Academic grants and biotech financing can tighten, which slows lab spending.
  • Pharma and biotech budgets: Customers may cut or delay research projects.
  • Competition: Larger life sciences suppliers compete in many of the same product categories.
  • Currency and trade: International sales expose results to exchange rates and tariffs.
  • Execution risk: New instruments and diagnostic products may be adopted more slowly than expected.

What to watch

  • Organic revenue growth by segment
  • Demand from biotech and pharma customers versus academic customers
  • Instrument sales and the pace of follow-on consumable orders
  • Research funding conditions, including government grant policy
  • Progress of diagnostics and spatial biology products

Options income angle

TECH options are listed across several expirations but usually trade less actively than those on the largest stocks, so bid-ask spreads can be wider, especially on strikes far from the current price.

Implied volatility tends to rise ahead of quarterly earnings and when the market reassesses life sciences spending, then fall once those events pass.

One caution for premium sellers: earnings or guidance can move the stock sharply, and thin option markets can make it hard to close or adjust a position at a fair price.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended June 30, 2026, filed August 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Bio-Techne agreed on June 25, 2026 to be acquired by Merck KGaA, Darmstadt, Germany, with each share converted into the right to receive $73.00 in cash. The deal is expected to close by late 2026 or early 2027, and it shapes much of the filing. Underneath it, fiscal 2026 sales were flat, and the company reported pricing pressure and an unfavorable product mix.

How the business did

  • Consolidated net sales remained flat at $1.2 billion. Organic revenue (sales excluding acquisitions, currency effects and businesses held for sale) was also flat.
  • Net earnings increased 148%, helped by one-time items in the prior year: an impairment charge and an arbitration loss. Adjusted net earnings, which strips out items such as stock compensation and restructuring, decreased 1%, which management attributed to unfavorable product mix and pricing pressures.
  • Protein Sciences net sales increased 1%, but its organic revenue decreased 1%. Diagnostics and Spatial Biology net sales decreased 3% after the Exosome Diagnostics divestiture, though its organic growth was 4%.
  • Gross margin was 65.8% versus 64.8% a year earlier. Adjusted gross margin was 69.6% versus 70.4%.
  • Cash from operations was $292.1 million. The company paid $49.9 million in dividends and repurchased $41.7 million of shares. Cash and investments stood at $264.7 million at June 30, 2026.

Risks specific to this company

  • Merger uncertainty: The deal needs shareholder approval and antitrust clearances. The company must pay Parent a termination fee of approximately $230.5 million in specified cases, and Parent must pay the company approximately $576.1 million in others, such as certain failures to obtain regulatory approval. Until closing, the agreement restricts acquisitions, borrowing and other actions, and the filing warns of employee and customer disruption.
  • Wilson Wolf purchase obligation: The company must buy the remaining 80.1% of Wilson Wolf on December 31, 2027. The second payment is approximately $1 billion plus potential contingent consideration.
  • Debt: The company has drawn $200.0 million on a $1 billion revolving credit facility with a variable interest rate. Covenants limit certain transactions, and a breach could make the debt immediately due.
  • Tariffs and international exposure: Approximately 48% of fiscal 2026 sales came from outside the U.S. Tariffs, including significant ones between the U.S. and China, raise the cost of imported supplies and may hurt demand if the company raises prices.
  • Diagnostics regulation and reimbursement: Changes in test reimbursement, regulation of lab developed tests, and the EU In Vitro Diagnostic Regulation could raise costs or reduce demand. The company is the sole manufacturer of a number of products for many customers.
  • Operations and goodwill: Significant operations sit in California near major earthquake faults. Goodwill was $975.4 million, about 38% of total assets, and an impairment would hit earnings.

What management is watching

  • Closing the Merger, including the required antitrust approvals and the shareholder vote, with completion expected by late 2026 or early 2027.
  • The Wilson Wolf acquisition, forecast between fiscal 2027 and fiscal 2028, which could be accelerated if Wilson Wolf meets certain financial milestones.
  • Spending: capital additions were $28.9 million in fiscal 2026, covering buildings, machinery and IT equipment. Research and development expenses decreased $4.7 million (5%).
  • Liquidity: management expects cash on hand, the credit line and operating cash flow to cover needs for at least the next 12 months, with $800.0 million of unused credit capacity.
  • Measures it points investors to: organic growth, adjusted gross margin, adjusted operating margin, adjusted net earnings and adjusted effective tax rate. These are non-GAAP measures, meaning they are not calculated under standard accounting rules.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Bio-Techne reported net sales of $299.7 million for the quarter ended September 30, 2026, an increase of 5%. Costs grew faster than sales, and earnings before taxes under standard accounting rules (GAAP) were lower than a year earlier. The pending acquisition by Merck KGaA, Darmstadt, Germany passed a shareholder vote on September 23, 2026, and is expected to close by late 2026 or early 2027.

How the business did

  • Sales: This is the first quarter of fiscal 2027, so the quarter is also the year to date. Organic revenue rose 7%. Organic revenue strips out currency swings, recent acquisitions and businesses held for sale. Foreign currency had an immaterial effect, and a business held for sale had an unfavorable impact of 2%.
  • Segments: Protein Sciences net sales were $219.7 million, up 9%, with operating margin of 37.9% versus 38.4%. Diagnostics and Spatial Biology net sales were $80.2 million, up 1%, with operating margin of 7.4% versus 11.2%.
  • Profit: Gross margin was 65.6%, unchanged. Adjusted gross margin was 69.3% versus 70.2%. Selling, general and administrative expenses rose 15% to $133.7 million, and research and development rose 9% to $26.3 million. GAAP earnings before taxes were $34,693 thousand versus $47,991 thousand. Adjusted diluted earnings per share were $0.44 versus $0.42. Acquisition related expenses and other, which are added back in the adjusted figures, were $17,906 thousand versus $3,508 thousand.
  • Cash and capital return: Operating cash flow was $73.1 million versus $27.6 million, mainly from the timing of payments. Cash was $350.0 million, up from $264.7 million at June 30, 2026. The company paid dividends of $12.6 million and did not draw on its credit line.

What management is watching

  • Spending and costs: Capital expenditures for the rest of fiscal 2027 are expected to be approximately $28 million, to add capacity for expected sales growth. Management also points to increasing R&D and SG&A expenses.
  • Tax rate: Excluding discrete items, the company expects an income tax rate of 23% to 27% for the rest of fiscal 2027.
  • Wilson Wolf purchase: The company must buy the remaining 80.1% of Wilson Wolf on December 31, 2027, or earlier if certain milestones are met. The payment is approximately $1 billion plus potential contingent consideration, forecast between fiscal 2027 and fiscal 2028. The credit line, with $800.0 million available, matures August 31, 2027.
  • Measures to watch: Management directs investors to organic revenue, adjusted gross margin, adjusted operating margin, adjusted net earnings and earnings per share, and the adjusted effective tax rate. It says these help compare periods.

Follow TECH in Kortex

The Kortex app shows TECH's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.